Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Type:
Application
Filed:
October 19, 2023
Publication date:
March 7, 2024
Applicant:
Prilenia Neurotherapeutics Ltd.
Inventors:
Michael HAYDEN, Spyridon PAPAPETROPOULOS, Juha-Matti SAVOLA, Eli EYAL, Beth BOROWSKY, Igor D. GRACHEV, Mark Forrest GORDON
Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.
Type:
Application
Filed:
October 19, 2023
Publication date:
February 15, 2024
Applicant:
Prilenia Neurotherapeutics Ltd.
Inventors:
Michael HAYDEN, Mahmoud Abdulhossein Pouladi
Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.
Type:
Application
Filed:
October 23, 2023
Publication date:
February 8, 2024
Applicant:
Prilenia Neurotherapeutics Ltd.
Inventors:
Daniella LICHT, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds or pharmaceutical acceptable salt thereof disclosed herein, so as to thereby treat the subject.
Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds 1-8 or pharmaceutical acceptable salt thereof described herein, effective to reduce anxiety and/or depression in a subject.
Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Type:
Grant
Filed:
February 24, 2019
Date of Patent:
November 28, 2023
Assignee:
PRILENIA NEUROTHERAPEUTICS LTD
Inventors:
Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor D. Grachev, Mark Forrest Gordon
Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
Abstract: This invention provides a method of maintaining, improving or lessening the decline of functional capacity or motor function in a human patient in a human patient with Huntington disease (HD) comprising orally administering to the patient a pharmaceutical composition comprising pridopidine.
Abstract: The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
August 29, 2023
Assignee:
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors:
Hermann Kurt Russ, Michal Geva, Ralph Laufer, Aric Orbach
Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
Type:
Application
Filed:
November 19, 2020
Publication date:
June 1, 2023
Applicant:
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors:
Michal GEVA, Ralph LAUFER, Michael HAYDEN
Abstract: This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.
Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.
Type:
Grant
Filed:
October 3, 2019
Date of Patent:
October 18, 2022
Assignees:
Prilenia Neurotherapeutics Ltd., The Board of Regents of the University of Texas System
Inventors:
Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.
Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
August 9, 2022
Assignee:
Prilenia Neurotherapeutics Ltd.
Inventors:
Michal Geva, Ralph Laufer, Michael Hayden, Neta Zach
Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Type:
Application
Filed:
January 31, 2022
Publication date:
June 30, 2022
Applicants:
PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventors:
Michael HAYDEN, Mahmoud Abdulhossein POULADI